Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Uscom Limited ( (AU:UCM) ).
Uscom Limited released its quarterly cash report for the period ending December 31, 2024, showing a cash balance of $2.17 million, a 56% increase from the previous period. Despite facing international market uncertainties, Uscom has made strategic moves by appointing SinoPharm as its distributor in China and obtaining regulatory approvals for its BP+ and SpiroSonic devices, which are expected to boost sales in the latter half of 2025.
More about Uscom Limited
Uscom Limited is an innovative medical technology company specializing in the development and marketing of non-invasive cardiovascular and pulmonary medical devices. The company’s product portfolio includes the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and Uscom SpiroSonic digital ultrasonic spirometers, which are designed for use in various medical fields such as pediatrics, emergency medicine, and home care. Uscom aims to improve clinical outcomes through leadership in science and is focused on global distribution with regulatory approvals in multiple regions.
YTD Price Performance: 0.0%
Average Trading Volume: 44,318
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$7.51M
Find detailed analytics on UCM stock on TipRanks’ Stock Analysis page.
